Exclusive: ‘If you could hallucinate a protein’: Profluent snags $35M for generative AI models
21 Mar 2024
Gene Therapy
A small startup in Berkeley, CA, wants to help create the next wave of custom enzymes for gene editing systems with the help of generative AI.
To get there, Profluent reeled in another $35 million in funding, added the former head of product at OpenAI to its board and brought in a chief business officer with BD experience at Editas, Tome and Vor.
Spark Capital led the new financing, disclosed Thursday morning. Existing investors Insight Partners and Air Street Capital returned, and angel investors like Google DeepMind chief scientist Jeff Dean also took part in the round, which builds onto the $9 million the company
emerged with in January 2023
.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.